Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1915.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,914.0,1.0,=,2.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1170.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,669.0,1.0,=,1.7
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,672.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,398.0,1.0,=,1.7
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,571.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,441.0,1.0,=,1.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3338.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1463.0,1.0,=,2.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3486.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1042.0,1.0,=,3.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2294.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1092.0,1.0,=,2.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,697.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,231.0,1.0,=,3.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2572.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,950.0,1.0,=,2.7
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,939.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,507.0,1.0,=,1.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1445.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,416.0,1.0,=,3.5
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,2205.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,370.0,1.0,=,6.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1689.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,560.0,1.0,=,3.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,3189.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,1095.0,1.0,=,2.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 1,None,BNT162b2,2,1m,Human,Wild Type (B.1),=,1352.0,1.0,Delta,19,T19R + G142D + Δ156-157 + R158G + L452R + T478K + P681R + D950N,1,=,594.0,1.0,=,2.3